Johnson & Johnson
JNJ
$235.18
-0.20%
Johnson & Johnson is the world's largest and most diversified healthcare company, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). It is a dominant market leader with a century-long reputation for stability, a massive global footprint, and a deep pipeline across immunology, oncology, and neurology. The current investor narrative is focused on the company's post-consumer business transformation following the Kenvue spin-off, its aggressive pursuit of a $50 billion oncology revenue goal through strategic acquisitions like Firefly Bio, and navigating the impending patent cliff for its blockbuster drug Stelara, which creates a significant near-term growth headwind.…
JNJ
Johnson & Johnson
$235.18
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: Hold. JNJ is a high-quality, defensive compounder with a robust balance sheet and shareholder-friendly capital allocation, but its near-term growth path is clouded by the Stelara patent cliff, creating a balanced risk/reward profile at current levels. This aligns with the analyst consensus which, while bullish on price targets, implies a period of digestion after a major rally.
Supporting Evidence: The stock's forward PE of 18.94x is reasonable for a healthcare leader but not cheap, especially against a backdrop of decelerating sequential revenue growth. The implied 37% upside to the average analyst target is compelling but hinges on successful pipeline execution. Profitability remains a key strength, with TTM operating margins of 27.17% and net margins of 28.46%. The massive $19.7B TTM free cash flow underpins the secure 2.46% dividend yield and future M&A, providing a floor for the stock.
Risks & Conditions: The two biggest risks are the Stelara patent cliff's impact on 2026-2027 earnings and the stock's technical vulnerability after a 54% yearly rally. This Hold rating would upgrade to a Buy if the stock pulls back to the $220-$230 range (offering a better entry point) or if Q3/Q4 2026 earnings demonstrate clear success in offsetting Stelara declines with new product growth. It would downgrade to a Sell if revenue growth turns negative YoY or if the forward PE expands above 22x without a corresponding acceleration in growth forecasts. Relative to its own history and the sector, JNJ is currently fairly valued, pricing in both its stability and its near-term challenges.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ is a quintessential 'Hold' at current levels. The company's quality is undeniable, but the stock is in a wait-and-see period where the market is pricing in a successful navigation of the Stelara patent cliff. The low beta and high cash flow make it a core holding for defensive portfolios, but aggressive growth investors will find more compelling opportunities elsewhere. The stance would turn bullish on a pullback to the $220-$230 range or on evidence of accelerating ex-Stelara growth. It would turn bearish if the Stelara decline accelerates beyond management's guidance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $305.73 and implied upside of +30.0% versus the current price.
Average Target
$305.73
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$188 - $306
Analyst target range
The stock is covered by 15 analysts, indicating substantial institutional interest. The consensus sentiment leans bullish, as evidenced by recent actions from major firms including RBC Capital (Outperform), HSBC (Buy), Citigroup (Buy), and a notable upgrade from Morgan Stanley to Overweight. The average target price implied by the estimated EPS of $17.48 and a forward PE of 18.94x is approximately $331, which suggests a significant implied upside of over 37% from the current price of $240.87. The target range, derived from estimated EPS, spans from a low of $16.86 to a high of $17.85. The high end of the range likely assumes successful pipeline execution, market share gains in MedTech, and effective management of the Stelara patent cliff, potentially leading to multiple expansion. The low end likely factors in more aggressive competitive pressures, faster-than-expected erosion of key drug sales, or broader macroeconomic headwinds impacting healthcare spending. The recent pattern of reiterated bullish ratings and one significant upgrade signals strengthening analyst conviction in the company's post-spin-off strategy and long-term growth trajectory.
Bulls vs Bears: JNJ Investment Factors
The bull case, anchored in JNJ's unparalleled financial strength, analyst conviction, and strategic pipeline build-out, currently holds stronger evidence due to the company's proven operational excellence and defensive characteristics. However, the bear case presents a clear and imminent threat in the form of the Stelara patent cliff, which is already impacting sales. The single most important tension in the investment debate is the race between the erosion of legacy blockbuster revenues and the commercial launch and scale-up of new pipeline assets and acquisitions. The resolution of this timing mismatch will determine whether JNJ can sustain its premium valuation and growth trajectory over the next 12-24 months.
Bullish
- Exceptional Financial Health & Cash Flow: JNJ's fortress balance sheet, with a conservative debt-to-equity ratio of 0.59 and TTM free cash flow of $19.7 billion, provides immense strategic flexibility. This allows for aggressive R&D, strategic acquisitions like the recent $1B Firefly Bio deal, and consistent shareholder returns without financial strain.
- Strong Analyst Conviction & Upside Potential: Coverage by 15 analysts shows strong institutional interest, with recent upgrades (e.g., Morgan Stanley to Overweight) and an average implied target price of ~$331. This represents a significant 37% upside from the current price of $240.87, signaling high conviction in the post-spin-off strategy.
- Powerful Long-Term Uptrend & Defensive Profile: The stock has gained 53.75% over the past year and trades at 96% of its 52-week high, demonstrating powerful momentum. Its low beta of 0.256 makes it approximately 75% less volatile than the SPY, offering a defensive characteristic attractive in uncertain markets.
- Robust Profitability & High Margins: The company maintains exceptional profitability, with a Q4 2025 gross margin of 86.37% and a TTM net margin of 28.46%. The operating margin of 27.17% reflects highly efficient operations, providing a strong earnings base to navigate near-term headwinds.
Bearish
- Imminent Stelara Patent Cliff: The impending loss of exclusivity for blockbuster drug Stelara creates a significant, quantifiable near-term growth headwind. Recent Q1 2026 earnings were overshadowed by a 'steep sales decline' for Stelara, directly threatening revenue growth which has already shown sequential deceleration.
- Extended Valuation & Technical Resistance: Trading at 96% of its 52-week high ($251.71) after a 53.75% rally, the stock is technically extended and susceptible to profit-taking. The forward PE of 18.94x, while not historically extreme, leaves little room for error and could compress if growth falters.
- Recent Relative Underperformance: Despite the long-term uptrend, JNJ has underperformed the broader market recently, with a 3-month relative strength of -12.27% versus the SPY. This short-term consolidation (-0.27% over 3 months) suggests weakening momentum as it approaches key resistance.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 9.08% YoY, the sequential quarterly trend from Q1 to Q4 2025 ($21.89B, $23.74B, $23.99B, $24.56B) shows growth is positive but not accelerating. This raises questions about the company's ability to offset the Stelara cliff with new products swiftly enough.
JNJ Technical Analysis
The stock is in a sustained, powerful uptrend, evidenced by a remarkable 53.75% gain over the past year. As of the latest close at $240.87, the price is trading near the top of its 52-week range, approximately 96% of the way from its low of $149.04 to its high of $251.71, indicating strong momentum but also proximity to a major technical resistance level. Recent momentum shows a divergence; while the 1-month performance is positive at +4.54%, the 3-month change is slightly negative at -0.27%, suggesting a period of consolidation or pullback after the explosive longer-term rally. This short-term pause is further highlighted by the stock's 3-month relative strength of -12.27% versus the SPY, indicating recent underperformance against the broader market. Key technical support is anchored at the 52-week low of $149.04, while immediate resistance sits at the 52-week high of $251.71. A decisive breakout above $251.71 would signal a continuation of the primary bull trend, whereas a failure and reversal could indicate a double-top formation. The stock exhibits low market-relative volatility, with a beta of 0.256, meaning it is approximately 75% less volatile than the SPY; this defensive characteristic is typical for a healthcare giant and informs position sizing for risk-averse portfolios. The current price's position 96% into its yearly range suggests the stock is extended and may be susceptible to profit-taking near the all-time high resistance.
Beta
0.26
0.26x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$149-$252
Price range past year
Annual Return
+51.5%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | +3.7% | +1.5% |
| 3m | -0.9% | +13.4% |
| 6m | +12.9% | +10.9% |
| 1y | +51.5% | +24.5% |
| ytd | +13.4% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth remains positive but is showing signs of deceleration on a sequential basis. The most recent quarterly revenue (Q4 2025) was $24.56 billion, representing a solid 9.08% year-over-year increase. However, examining the trend from Q1 to Q4 2025 reveals revenue figures of $21.89B, $23.74B, $23.99B, and $24.56B, indicating growth is present but not accelerating sharply. Segment data shows the Innovative Medicine division, at $15.76 billion, is the primary growth driver, significantly larger than the MedTech segment's $8.80 billion. The company is highly profitable, with Q4 2025 net income of $5.12 billion and a robust gross margin of 86.37%. Profitability metrics are strong but have shown some quarterly fluctuation; for instance, the net income margin was 20.83% in Q4 2025, down from an exceptional 50.24% in Q1 2025 which was boosted by a large one-time other income item. The trailing twelve-month net margin is a healthy 28.46%, and the operating margin stands at 27.17%, reflecting efficient operations. Financial health is exceptionally strong, underpinned by a fortress balance sheet. The debt-to-equity ratio is a conservative 0.59, indicating a balanced capital structure with more equity than debt. Liquidity is adequate with a current ratio of 1.03. Most impressively, the company generates massive cash flows, with TTM free cash flow of $19.70 billion, providing ample internal funding for dividends, share buybacks, and strategic acquisitions like the recent $1 billion Firefly Bio deal, without reliance on excessive external financing.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's consistent profitability with net income of $5.12 billion in the last quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 18.81x, while the forward PE is slightly higher at 18.94x; the minimal gap suggests the market expects stable, but not accelerating, earnings growth in the near term. Compared to the broader Drug Manufacturers industry, JNJ's valuation presents a mixed picture. Its trailing PE of 18.81x is generally in line with or at a slight premium to many large-cap pharmaceutical peers, which is often justified by its superior diversification, AAA-rated balance sheet, and reliable dividend king status. The stock's Price-to-Sales ratio of 5.35x and EV/EBITDA of 12.97x are also key benchmarks for sector comparison. Historically, JNJ's current trailing PE of 18.81x sits below its own multi-year range observed in the provided data, which has seen peaks above 30x and troughs in the mid-teens. This positioning suggests the stock is not at historical valuation extremes; it is trading closer to the midpoint of its historical band, implying the market is pricing in a balanced outlook that acknowledges both its stable cash flows and the growth headwinds from key drug patent expirations, rather than overly optimistic or pessimistic expectations.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's primary financial risk is not solvency—its 0.59 debt-to-equity ratio and $19.7B TTM FCF are exemplary—but rather earnings volatility and growth sustainability. The company faces a significant revenue concentration risk with the impending patent expiry of Stelara, a key profit driver. While Q4 2025 net income was a robust $5.12B, the net income margin fluctuated from 50.24% in Q1 2025 (boosted by a one-time gain) to 20.83% in Q4, highlighting underlying earnings variability. The valuation (forward PE 18.94x) depends on the assumption that new products can fill the Stelara gap without a prolonged growth hiatus.
Market & Competitive Risks: The stock trades at a premium valuation relative to some healthcare peers, with a PS ratio of 5.35x and EV/EBITDA of 12.97x. A failure to meet growth expectations could trigger multiple compression. While its low beta of 0.256 offers defensive appeal, it also means the stock may not participate fully in strong bull markets, as seen in its recent 3-month underperformance versus the SPY. Competitively, the pharmaceutical and MedTech landscapes are intensifying, with rivals like Eli Lilly aggressively advancing their own pipelines, potentially pressuring JNJ's market share and pricing power in key therapeutic areas.
Worst-Case Scenario: The worst-case scenario involves a faster-than-expected erosion of Stelara sales coinciding with clinical or regulatory setbacks in key pipeline candidates like those from the Firefly Bio acquisition. This could lead to consecutive quarters of revenue misses, analyst downgrades, and a derating of the stock's multiple towards its historical trough PE levels. A realistic downside could see the stock re-testing its 52-week low of $149.04, which would represent a decline of approximately -38% from the current price of $240.87. While such a severe drawdown is unlikely given the company's fundamentals, a move to the $200-$210 support zone (a -13% to -17% decline) is plausible if near-term execution falters.
FAQ
The key risks, in order of severity, are: 1) Product Concentration & Patent Risk: The imminent loss of exclusivity for blockbuster drug Stelara creates a significant, near-term revenue headwind already evidenced in recent sales declines. 2) Execution & Pipeline Risk: The ambitious $50B oncology goal depends on successful integration of acquisitions (e.g., Firefly Bio) and flawless clinical development; any setback could delay growth. 3) Valuation & Technical Risk: After a 54% yearly rally, the stock trades at 96% of its 52-week high, making it susceptible to profit-taking and multiple compression if growth disappoints. 4) Competitive Risk: Intense rivalry in pharmaceuticals and MedTech could pressure pricing and market share.
The 12-month forecast for JNJ is a range-bound advance with a positive bias, centered on the analyst average implied target near $331 (37% upside). Our scenario analysis assigns a 60% probability to a base case target of $300-$325, where the company manages the Stelara transition as expected. A bull case (30% probability) to $330-$350 requires flawless pipeline execution, while a bear case (10% probability) to $200-$225 involves steeper sales erosion and setbacks. The most likely outcome is the base case, predicated on JNJ's historical execution prowess and financial strength offsetting known headwinds.
JNJ is fairly valued relative to its own history and sector peers. Its forward PE of 18.94x and PS ratio of 5.35x are in line with or at a slight premium to large-cap pharmaceutical peers, justified by its AAA-rated balance sheet and diversification. Historically, its trailing PE of 18.81x sits below peaks above 30x, suggesting it is not at an extreme. The valuation implies the market expects JNJ to successfully navigate the Stelara patent cliff with low-single-digit organic growth, supported by its pipeline and M&A—a balanced, not overly optimistic, outlook.
JNJ is a good stock to buy for conservative, income-oriented investors with a long-term horizon who prioritize capital preservation and steady dividend growth. At the current price of $240.87, it is fairly valued with a forward PE of 18.94x, not cheap enough for deep-value investors but reasonable for its quality. The significant 37% implied upside to analyst targets is attractive but requires patience. The biggest downside risk is a faster-than-expected decline in Stelara sales. It is a better buy on a pullback towards $220-$230 for those not already holding it.
JNJ is unequivocally suitable for long-term investment, not short-term trading. Its low beta of 0.256 means it has low volatility and is unlikely to generate swift trading gains. As a Dividend King with a 2.46% yield, it is a core holding for compounding income over decades. The current investment narrative revolves around a multi-year patent cliff transition, making short-term price movements noisy and less meaningful. Investors should have a minimum holding period of 3-5 years to allow the company's strategy to play out and to fully benefit from its defensive characteristics and dividend growth.
